Summary
Conclusion
the dossier summarised in one paragraphThe computed 12-month bankruptcy probability of YNIOS Pharma is 0.8% (low). The 2024 annual accounts show equity of €702k and a net result of €342k. Equity is growing by ~417.3% per year across the filed fiscal years. Its solvency ranks better than 85% of 52 sector peers (fiscal year 2024). The company has been active since 2022 and the Belgian State Gazette contains no insolvency or warning signals.
Based on the State Gazette, CBE and 3 annual accounts.
Signals
2 signals · with evidenceSignals are derived from the filed annual accounts and the sector comparison. No composite score: each signal is separately verifiable at the source.
Filing behaviour
From the deposit records, complete market-wide| Year closed | Due by | Filed | Variance | Reference |
|---|---|---|---|---|
| 31-12-2025 | 31-07-2026 | nothing on record | not filed | - |
| 31-12-2024 | 31-07-2025 | 01-08-2025 | 1 d late | 2025-00348564 |
| 31-12-2023 | 31-07-2024 | 02-07-2024 | 29 d early | 2024-00195250 |
| 31-12-2022 | 31-07-2023 | 13-07-2023 | 18 d early | 2023-00238825 |
Source: the National Bank's deposit records. Those records are complete, including for years whose figures we have not read yet. Filing late covers nearly half the market and is therefore not scored; only not filing, being more than 90 days late and breaking a punctual record carry weight.
Trust signals
2 signalsAdministrative Flags
Bankruptcy probability (12 mo)
Checked model v1 · free for everyoneStatistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Financials
Annual accounts & ratios
Source: NBB · 2024How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 72.4% | 3.8% | |
| Net result | €342k | €-6k | |
| Equity | €702k | €2k | |
| Gross operating margin | €393k | €-2k | |
| Total assets | €970k | €87k |
| Fiscal year | 2024 |
|---|---|
| Deposit | micro |
| Revenue | - |
| EBITDA | €392k |
| Net profit | €342k |
| Cash flow | €392k |
| Staff costs | - |
| Income taxes | - |
| Dividends | - |
| Total assets | €970k |
| Equity | €702k |
| Debt | €268k |
| of which ≤ 1y | €268k |
| of which > 1y | - |
| Working capital | €-1k |
| Employees (FTE) | - |
| 2024 | |
|---|---|
| Current ratio | 0.99 |
| Quick ratio | 0.99 |
| Working capital ratio | -0.1% |
| Solvency | 72.4% |
| Debt / equity | 0.38 |
| Long-term debt ratio | - |
| Interest coverage | 326.29 |
| Gross margin | - |
| Net margin | - |
| ROA | 35.3% |
| ROE | 48.7% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2024 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €970k |
| Fixed assets | 21/28 | €704k |
| Intangible fixed assets | 21 | €704k |
| Current assets | 29/58 | €266k |
| Amounts receivable within one year | 40/41 | €9k |
| Cash & bank | 54/58 | €257k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €970k |
| Equity | 10/15 | €702k |
| Contributions / capital | 10/11 | €692k |
| Accumulated profits (losses) | 14 | €11k |
| Amounts payable | 17/49 | €268k |
| Amounts payable within one year | 42/48 | €268k |
| Trade debts payable within one year | 44 | €7k |
| Income statement | ||
| Gross operating margin | 9900 | €393k |
| Operating result | 9901 | €343k |
| Financial income | 75 | €236 |
| Financial charges | 65 | €1k |
| Result before taxes | 9903 | €342k |
| Net result for the period | 9904 | €342k |
| Result to be appropriated | 9905 | €342k |
Health barometer
FY 2024 · computedUnlock the full score breakdown, per-year score history and the indicative credit limit from Kantoor S.
See plans →Locations & real estate
Registered office
from the Crossroads BankThis address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Avenue Wolfers 321310 La HulpeReal-estate footprint
Source: CBE × cadastre · address linkingParcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 25050F0026/00P017 | Wallonia | 1,390 m² | 1 · 394 m² | 14.5 m · 3 fl. |
Publications
Lifecycle & Insolvency Signals
Belgisch Staatsblad · acts
4 acts06-12-2024 Restructuring of share classes
10-06-2024 Publication in the Belgian Official Gazette, Miscellaneous
25-01-2023 Restructuring of share classes
28-09-2022 Restructuring of share classes
Analysis
Snowflake analysis
financial profile on 5 axesExceptional profile, strong across almost every axis.
All 5 axes are computed from data Checked has read.
Ask AI about this company
Checked AISoon: ask questions about this dossier, risks, curator, sector comparison, answered from the official data on this page.
AI due-diligence brief
Checked AIGenerate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
Credit advice
verdict per customer and amountSimilar
Similar companies
Comparable size, same sectorCompany registry
Company registry (CBE)
Crossroads Bank| Legal nameFR | YNIOS Pharma |